Holen Sie sich die Stockscreener-App
6.93
1.32%
0.09
Handel nachbörslich:
6.93
Schlusskurs vom Vortag:
$6.84
Offen:
$6.82
24-Stunden-Volumen:
381.94K
Relative Volume:
0.71
Marktkapitalisierung:
$372.46M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-4.3861
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
-3.21%
1M Leistung:
-0.43%
6M Leistung:
+43.18%
1J Leistung:
+13.61%
1-Tages-Spanne:
$6.555
$7.12
1-Wochen-Bereich:
$6.155
$7.7024
52-Wochen-Spanne:
$2.315
$10.13
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie FULC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
6.93 | 372.46M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-23 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Bank of America Corp DE Has $432,000 Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Research Analysts Issue Forecasts for FULC FY2026 Earnings - Defense World
Citadel Advisors LLC Makes New $69,000 Investment in Lisata Therapeutics, Inc. (NASDAQ:LSTA) - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Millennium Management LLC - Defense World
Comparing Fulcrum Therapeutics (NASDAQ:FULC) and Lakeshore Biopharma (NASDAQ:LSB) - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Two Sigma Investments LP - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics Awards Major Stock Options Package: 70,000 Shares at $6.96 Exercise Price - Stock Titan
Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory - MSN
BNP Paribas Financial Markets Makes New Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) shareholders are up 16% this past week, but still in the red over the last five years - simplywall.st
Fulcrum Therapeutics to Present at Upcoming Medical Meetings | FULC Stock News - GuruFocus
Fulcrum Therapeutics to Present at Upcoming Medical Meetings - Eagle-Tribune
New Oral Sickle Cell Drug Shows Promise: Fulcrum to Reveal Phase 1 Trial Results at Global Medical Conferences - Stock Titan
Fulcrum Therapeutics to Participate in the 46th Annual Goldman S - GuruFocus
Fulcrum Therapeutics (FULC) Target Price Raised Amid Key Data An - GuruFocus
FULC: Piper Sandler Raises Price Target for Fulcrum Therapeutics | FULC Stock News - GuruFocus
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | FULC Stock News - GuruFocus
Rare Disease Innovator Fulcrum Therapeutics Takes Stage at Elite Goldman Sachs Healthcare Conference - Stock Titan
Fulcrum gains as Leerink upgrades ahead of data for lead asset - MSN
Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at Leerink Partners - Defense World
Leerink Partnrs Upgrades Fulcrum Therapeutics (NASDAQ:FULC) to Strong-Buy - Defense World
Leerink raises Fulcrum Therapeutics stock to Outperform By Investing.com - Investing.com Canada
Northern Trust Corp Buys 142,578 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics Shares Rise After Upgrade From Leerink - marketscreener.com
Fulcrum stock gains as Leerink upgrades (FULC:NASDAQ) - Seeking Alpha
Fulcrum Therapeutics (FULC) Receives Analyst Upgrade and Increas - GuruFocus
Leerink Partners Upgrades Fulcrum Therapeutics (FULC) - Nasdaq
Leerink Upgrades Fulcrum Therapeutics to Outperform From Market Perform, Adjusts Price Target to $12 From $4 - marketscreener.com
Fulcrum Therapeutics (FULC) Receives Analyst Upgrade on Positive Outlook | FULC Stock News - GuruFocus
Fulcrum Therapeutics at RBC Capital: Strategic Steps in Sickle Cell Treatment - Investing.com Canada
Cantor Fitzgerald Predicts FULC FY2025 Earnings - Defense World
Price T Rowe Associates Inc. MD Raises Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.67 Average Price Target from Analysts - Defense World
Cantor Fitzgerald Upgrades Fulcrum Therapeutics (FULC) - Nasdaq
Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade - marketscreener.com
Fulcrum Therapeutics (FULC) Upgraded to Overweight by Cantor Fit - GuruFocus
Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight From Neutral, Price Target is $10 - marketscreener.com
FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 - GuruFocus
FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 Target | FULC Stock News - GuruFocus
Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with P - GuruFocus
Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with Positive Outlook | FULC Stock News - GuruFocus
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Dimensional Fund Advisors LP - Defense World
Wells Fargo & Company MN Has $161,000 Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Monday - Defense World
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fulcrum Therapeutics Inc-Aktie (FULC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sapir Alex | See Remarks |
Jul 03 '24 |
Option Exercise |
3.27 |
150,000 |
490,500 |
193,360 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):